These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22652709)

  • 21. Low-Polydispersity Glucose Polymers as Osmotic Agents for Peritoneal Dialysis.
    Leypoldt JK; Hoff CM; Akonur A; Holmes CJ
    Perit Dial Int; 2015; 35(4):428-35. PubMed ID: 24584616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis.
    Woodrow G; Stables G; Oldroyd B; Gibson J; Turney JH; Brownjohn AM
    Nephrol Dial Transplant; 1999 Jun; 14(6):1530-5. PubMed ID: 10383020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of icodextrin on the peritoneal membrane.
    Krediet RT
    Nephrol Dial Transplant; 2010 May; 25(5):1373-5. PubMed ID: 20172851
    [No Abstract]   [Full Text] [Related]  

  • 24. Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange.
    Davies SJ; Garcia Lopez E; Woodrow G; Donovan K; Plum J; Williams P; Johansson AC; Bosselmann HP; Heimburger O; Simonsen O; Davenport A; Lindholm B; Tranaeus A; Divino Filho JC
    Nephrol Dial Transplant; 2008 Sep; 23(9):2982-8. PubMed ID: 18456678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peritoneal dialysis solution and nutrition.
    Verger C
    Contrib Nephrol; 2012; 178():6-10. PubMed ID: 22652708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of fill volume on ultrafiltration with icodextrin in children on chronic peritoneal dialysis.
    Rousso S; Banh TM; Ackerman S; Piva E; Licht C; Harvey EA
    Pediatr Nephrol; 2016 Oct; 31(10):1673-9. PubMed ID: 27178072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Icodextrin: What arguments for and against its use as an osmotic agent in peritoneal dialysis].
    Savenkoff B; Flechon-Meibody F; Goffin É
    Nephrol Ther; 2018 Jun; 14(4):201-206. PubMed ID: 29291942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription.
    Habib AM; Preston E; Davenport A
    Nephrol Dial Transplant; 2010 May; 25(5):1633-8. PubMed ID: 20037174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When should icodextrin be started to improve atherosclerosis in peritoneal dialysis patients?
    Hiramatsu T; Hayasaki T; Hobo A; Furuta S; Kabu K; Tonozuka Y; Iida Y
    Adv Perit Dial; 2013; 29():4-8. PubMed ID: 24344482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro.
    Cooker LA; Choo CG; Luneburg P; Lamela J; Holmes CJ
    Adv Perit Dial; 1999; 15():17-20. PubMed ID: 10682065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring new evidence of the clinical benefits of icodextrin solutions.
    Davies SJ
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 2():ii47-50. PubMed ID: 16825261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of icodextrin-based dialysis solution on peritoneal leptin clearance.
    Opatrná S; Opatrný K; Racek J; Sefrna F
    Perit Dial Int; 2003; 23(1):89-91. PubMed ID: 12691516
    [No Abstract]   [Full Text] [Related]  

  • 33. [Icodextrine peritoneal dialysis solution in clinical practice].
    Opatrná S
    Vnitr Lek; 2008 Dec; 54(12):1155-60. PubMed ID: 19140524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis.
    Woodrow G; Oldroyd B; Stables G; Gibson J; Turney JH; Brownjohn AM
    Nephrol Dial Transplant; 2000 Jun; 15(6):862-6. PubMed ID: 10831642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Icodextrin with small and short dwell enhances ultrafiltration in peritoneal dialysis patients with severe overhydration.
    Kuriyama S; Otsuka Y; Iida R; Matsumoto K; Hosoya T
    Perit Dial Int; 2006; 26(4):508-9. PubMed ID: 16881350
    [No Abstract]   [Full Text] [Related]  

  • 36. Echocardiographic, electrocardiographic and blood pressure changes induced by icodextrin solution in diabetic patients on peritoneal dialysis.
    Paniagua R; Orihuela O; Ventura MD; Avila-Díaz M; Cisneros A; Vicenté-Martínez M; Furlong MD; García-González Z; Villanueva D; Prado-Uribe MD; Alcántara G; Amato D
    Kidney Int Suppl; 2008 Apr; (108):S125-30. PubMed ID: 18379535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence-based medicine in peritoneal dialysis: peritoneal dialysis solutions.
    Feriani M
    Contrib Nephrol; 2003; (140):202-8. PubMed ID: 12800361
    [No Abstract]   [Full Text] [Related]  

  • 38. Practical considerations when prescribing icodextrin: a narrative review.
    Silver SA; Harel Z; Perl J
    Am J Nephrol; 2014; 39(6):515-27. PubMed ID: 24925229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of icodextrin on heart rate variability in diabetic patients on peritoneal dialysis.
    Orihuela O; de Jesús Ventura M; Ávila-Díaz M; Cisneros A; Vicenté-Martínez M; Furlong MD; García-González Z; Villanueva D; Alcántara G; Lindholm B; García-López E; Villanueva C; Paniagua R
    Perit Dial Int; 2014; 34(1):57-63. PubMed ID: 24525598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations for the use of icodextrin in peritoneal dialysis patients.
    Johnson DW; Agar J; Collins J; Disney A; Harris DC; Ibels L; Irish A; Saltissi D; Suranyi M
    Nephrology (Carlton); 2003 Feb; 8(1):1-7. PubMed ID: 15012742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.